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ABSTRACT
Chronic HCV infections represent a major worldwide
public health problem and are responsible for a large
proportion of liver related deaths, mostly because of
HCV-associated hepatocellular carcinoma and cirrhosis.
The treatment of HCV has undergone a rapid and
spectacular revolution. In the past 5 years, the launch of
direct acting antiviral drugs has seen sustained
virological response rates reach 90% and above for
many patient groups. The new treatments are effective,
well tolerated, allow for shorter treatment regimens and
offer new opportunities for previously excluded groups.
This therapeutic revolution has changed the rules for
treatment of HCV, moving the field towards an
interferon-free era and raising the prospect of HCV
eradication. This manuscript addresses the new
challenges regarding treatment optimisation in the real
world, improvement of antiviral efficacy in ‘hard-to-treat’
groups, the management of patients whose direct acting
antiviral drug treatment was unsuccessful, and access to
diagnosis and treatment in different parts of the world.
INTRODUCTION
The global burden of hepatitis is immense. Viral
hepatitis kills 1.45 million people worldwide each
year, which is as many as HIV and more than tuber-
culosis or malaria.1 Yet, while deaths from HIV/
AIDS have declined since 2010, hepatitis deaths
have risen. Of the hepatitis viruses, HBV and HCV
cause the vast majority of deaths, with hepatocellu-
lar carcinoma (HCC) and cirrhosis accounting for
most of them. Since 1990, deaths from HBV have
plateaued, while HCV deaths continue to rise and
are expected to do so at least for the next decade.2
Against this gloomy backdrop, the treatment of
HCV has undergone a revolution. In the past
5 years, the launch of direct acting antiviral drugs
(DAAs) has seen sustained virological response
(SVR) rates reach 95% and above for many patient
groups. The new treatments are effective, well tol-
erated, allow for shorter treatment regimens and
offer new opportunities for previously excluded
groups. This therapeutic revolution has changed
the rules for treatment of HCV, moving the field
towards an interferon (IFN)-free era and raising the
prospect of HCV eradication.3 4 Yet it raises further
questions. How do we optimise outcomes in the
real world? How can we improve results for
‘hard-to-treat’ groups? Is it better to treat HCV
before or after liver transplant (LT)? How should
we manage people whose DAA treatment is unsuc-
cessful? And—given the high price of these new
treatments—how can we improve access to diagno-
sis and treatment for those patients who need them
most?
Gut brought together some of the leading global
experts in HCV to discuss these questions and
point a way forward. The round table, held during
the European Association for the Study of the
Liver’s International Liver Congress 2015, brought
clarity to some of these issues and looked into the
future pipeline of HCV treatment. This article aims
to summarise that shared knowledge.
Treatment efficacy with currently available
drugs
The development of new generation DAAs with
much higher SVR rates has dramatically improved
the prospects for people infected with HCV. SVR
directly affects clinical outcomes and survival, low-
ering all cause mortality, as shown in cohort studies
and meta-analysis.5–7 A recent meta-analysis found
that mortality rates in those with SVR after
IFN-containing regimens, compared with those
without SVR, decreased by 62–84%, varying by
cirrhosis and co-infection with HIV. The risk of
HCC after 5 years was reduced from 9.3% to 2.9%
in mono-infected patients, from 13.9% to 5.3% in
patients with cirrhosis and from 10% to 0.9% in
HIV co-infected patients. Risk of LTwithin 5 years
for patients with cirrhosis reduced from 7.3% to
0.2%. SVR is also associated with a reduction in
extrahepatic disease associated with HCV such as
diabetes, kidney impairment, non-Hodgkin’s
lymphoma and cardiovascular complications.8 9
It will be necessary to follow patients treated suc-
cessfully with DAA-based therapy to establish the
long-term clinical benefits. But even so, these data
provide a strong argument for HCV treatment,
given the high cost of treating liver cancer and of
liver transplantation.
In 2011, the standard treatment regimen for
HCV was pegylated IFN plus ribavirin (PR) for 24
weeks or 48 weeks. PR therapy resulted in an SVR
in 45% of genotype 1 (G1) patients. The first gen-
eration of DAAs with protease inhibitors (PIs) used
in combination with PR pushed SVR rates up to
75%, but with a substantially increased side effect
burden4 which also limited eligibility to treat-
ment.10 With the development of additional classes
of DAAs (nucleotide and non-nucleotide inhibitors
of NS5B polymerase, second wave PIs, and NS5A
inhibitors), rates improved again. A combination of
DAA drugs, used in the first non-IFN regimens
with or without ribavirin, produce SVR rates of
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95% and above for (G1) patients. These new combinations have
better efficacy across genotypes, are better tolerated thus
improving treatment eligibility,5 allow a reduced treatment dur-
ation of 12 weeks or 24 weeks, and an easier dosing schedule
with a reduced pill burden. See table 1 for a summary of the
classes of new DAAs. While data exist for combinations of
DAAs with PR,11–14 IFN therapy is increasingly difficult to use
as patients are aware of the side effects and the existence of
alternative drug regimens.
The combination of two DAAs (NS5B inhibitor sofosbuvir
and NS5A inhibitor ledipasvir) cures >90% treatment-naive
patients without cirrhosis with G1 HCV in phase 3 studies.
Studies suggest there is no need to add ribavirin in this group,
or to extend beyond 12 weeks of treatment.15 16 It was even
suggested that shortening to 8 weeks of sofosbuvir/ledipasvir
might be sufficient to achieve cure in >90% naïve patients with
G1 HCV, low viral load (<6 log IU/mL) and without cirrhosis;17
this suggests an opportunity for shorter duration therapy with
even more potent antivirals, as discussed below. For patients
with cirrhosis, SVR rates with this dual therapy drop to 90%,
but addition of ribavirin and extension of treatment to 24 weeks
raises rates to 95%.15 18 19 This DAA combination is successful
even in patients with cirrhosis who had previously failed PR
and then a PI plus PR.19 Success rates drop by around 10%
with decompensated cirrhosis.20 We consider the challenge of
decompensated cirrhosis and treatment failure below.
Trials of the recently licensed three-dimensional (3D) combin-
ation (the PI paritaprevir boosted with ritonavir, combined with
NS5A inhibitor ombitasvir and NS5B inhibitor dasabuvir) show
similarly high SVR rates.21–24 For G1b, recent results suggest
there is no need to use ribavirin or extend treatment beyond
12 weeks, whether patients have cirrhosis or not.25 However,
the current label recommends ribavirin in patients with G1b
and cirrhosis. In contrast, patients with G1a appear to benefit
from the addition of ribavirin, and patients with cirrhosis may
require treatment extended to 24 weeks.22 26
G2 infected patients can usually be treated with a combin-
ation of sofosbuvir and ribavirin for 12 weeks, giving high rates
of SVR.27–31 Patients with cirrhosis, especially those who are
treatment experienced, may require longer treatment (16–
24 weeks) or the addition of an NS5A inhibitor to increase anti-
viral potency. HCV G3 is the new ‘hard-to-treat’ genotype, with
lower SVR rates, and is considered in more detail below.
Recent data for non-IFN treatment of G4 comes from a study
in mono-infected patients without cirrhosis, using the
combination of ombitasvir and paritaprevir with or without
ribavirin, for 12 weeks. SVR was 100% with ribavirin, 91%
without.32 In a recent study including 103 patients with G4,
sofosbuvir and ribavirin gave an SVR rate of 90% in those
treated for 24 weeks versus 77% with a 12 week course and
patients with cirrhosis at baseline had lower rates of SVR12
(78%; 24 weeks of therapy) than those without cirrhosis (93%;
24 weeks of therapy).33 In addition, real-world data of sofosbu-
vir plus simeprevir and sofosbuvir plus daclatasvir in
G4-infected patients showed high rates of SVR4 across 12-week
and 24 week regimens, with and without ribavirin.34 The results
of a recent single-centre, open-label cohort, phase 2a trial, in
patients with HCV G4, who were treatment-naive or IFN
treatment-experienced and received sofosbuvir and ledipasvir
combination for 12 weeks, showed that 20 (95%) of 21 patients
completed 12 weeks of treatment and achieved SVR12 (95%)
including 7 patients with cirrhosis.35 These results give promise
for IFN and ribavirin-free treatments for G4-infected patients.
Few trials have included participants with G5 and G6. A trial
including seven patients with G5 or G6 gave a 100% SVR rate
for the combination of PR plus sofosbuvir in treatment-naive
patients.29 Twenty-five patients with G6 treated with sofosbuvir
and ledipasvir for 12 weeks had a 96% SVR rate, suggesting
that this may be a good combination.36
The advances in therapy over the last few years are reflected
in clinical practice guidelines published by the European
Association for the Study of the Liver in April 2015, which can
be viewed at http://www.easl.eu/research/our-contributions/
clinical-practice-guidelines37 and by the American Association




▸ In trials, all-oral DAA regimens are available for all genotypes
and show remarkable efficacy with SVR rates consistently
90% or above
▸ From IFN-based treatments, SVR has a direct effect on
important clinical outcomes
▸ In trials, shorter treatment regimes without ribavirin are suit-
able for some genotypes and stages of disease
▸ However, while SVR rates are improved across most popula-
tions, better treatment options are needed for patients with
decompensated cirrhosis and cirrhosis with previous treat-
ment failure, especially those with G3
Questions:
▸ Should HCV screening and treatment be more widely
offered?
Optimal treatment in the real world
Translating clinical trial results into real-world practice provides
important information for clinicians, patients and policy
makers. While phase 3 trials include a relatively homogeneous
population, utilisation of HCV medications in the real world
often includes patients with more advanced liver disease or
medical comorbidities who may have been excluded from regis-
tration trials. Thus, safety and efficacy may differ in the
expanded population being treated with new agents.
Data from the HCV-TARGET cohort, an international longi-
tudinal observational study, demonstrated that DAA regimens
were generally safe and well tolerated in the real-world environ-
ment with low rates of serious adverse events or discontinua-
tions due to side effects.39 However, ongoing vigilance is
warranted as a recent advisory from regulatory authorities sug-
gested potentially serious interaction of sofosbuvir-containing
Table 1 Oral antivirals for hepatitis C: examples of drugs
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regimens with amiodarone that can result in severe, and even
fatal, bradycardias.40
Efficacy results from real-world studies are generally support-
ive of those found in clinical trials, although SVR rates are
somewhat lower in the expanded population. The
HCV-TARGET study of more than 700 patients with G1 treated
with the combination of sofosbuvir and simeprevir reported an
overall SVR rate of 87%. The study did not find a significant
impact of adding ribavirin in this context.41 Other smaller
studies gave similar results.42 The Hepather Cohort study with
more than 400 patients, the majority of whom were cirrhotic,
with G1 treated with sofosbuvir and daclatasvir reported higher
SVR rates when used for 24 weeks or with the addition of riba-
virin for 12 weeks.43 Data for real-world experience of treating
patients with G3 for 24 weeks with sofosbuvir and ribavirin
demonstrated SVR rates of 65%, with 30% relapse rates.44
Patients infected with G3 with cirrhosis and previous treatment
failure are emerging as the new difficult-to-treat population.
Recently, investigators assessed clinical data from electronic
medical records for 4026 patients with G1 or G2 HCV who
started sofosbuvir-based therapy for the recommended 12-week
duration through the US Department of Veterans Affairs, the
largest integrated national provider of HCV care in the USA. A
third of the patients were treatment-experienced. Among 3203
G1 patients, 1302 started sofosbuvir, peginterferon and riba-
virin; 1559, sofosbuvir plus simeprevir; and 342, sofosbuvir
+simeprevir+ribavirin. All 823 G2 patients started sofosbuvir
+ribavirin. The SVR rate seemed to be significantly lower by
15–20% than what was observed in the registration trials and in
patient cohorts followed in reference centres.45
Current DAA regimens are highly effective with few contrain-
dications to treatment such that the number of patients who are
potential treatment candidates is daunting. Therefore, it is
important to make the most of finite resources and to maximise
the cost-effectiveness of therapy. Perhaps the most important
factor in treatment success is adherence to treatment recommen-
dations. The patient’s commitment to therapeutic success
should be assessed prior to embarking on therapy. Assessment
should include factors that might interrupt treatment, such as
travel plans, work schedule and unstable social environment
unconducive to medication adherence. Patients who have been
living with HCV for many years, treated unsuccessfully with
various regimens, and who have been waiting for more effective
all-oral regimen therapy are usually well known to their clini-
cians and have demonstrated great capacity to be adherent to
even toxic regimens.
Pretreatment education is also important and may be the best
strategy for maximising adherence. Stressing the importance of
taking the medications each day and a discussion of the poten-
tial mild side effects will equip patients to self-manage their
regimens. Newly diagnosed patients may need more time to
process the consequences of HCV infection and the implications
of therapy. Clinicians need to be alert for this changing patient
profile as screening increases and treatment becomes more wide-
spread. Regardless of duration of HCV infection, however, a
patient’s needs should be individually addressed to maximise
adherence. The clinician needs to discuss adherence strategies
relative to the patient’s lifestyle, for example how to accommo-
date a pill regimen while working night shifts.
Before starting treatment, a comprehensive clinical and viro-
logical evaluation is needed, including staging of liver disease
for the presence of cirrhosis, virological evaluation for HCV
genotype and level of HCV RNA, and all current medications
should be evaluated for potential drug-drug interactions (DDIs).
This information is needed to choose the right treatment
regimen. For instance, many patients with HCV take acid-
suppressant therapy, which can diminish absorption of ledipas-
vir. Drug interactions can be checked on websites such as
(http://www.hep-druginteractions.org/).
Once treatment is underway, the clinician needs to put in
place a specific programme of visits and/or scheduled telephone
calls with a pharmacist or a nurse during treatment to monitor
treatment adherence, antiviral efficacy, potential side effects and
DDI. A challenge is to establish a practical intervention that
improves adherence rates at low cost to the clinic with minimal
inconvenience to the patient.
Five basic concepts apply when selecting the most appropriate
regimen for an individual patient:
▸ Viral genotype
▸ Prior treatment experience
▸ Presence of cirrhosis
▸ Comorbidities (especially renal insufficiency)
▸ Concurrent medications that interact with HCV DAAs.
Data from the trials discussed above have been translated into
guidelines for all-oral treatment of HCV infection.
Organisations issuing guidance include the food and drug
administration (FDA) via drug labels (ledipasvir and sofosbuvir
pack, simeprevir pack, ombitasvir, paritaprevir and ritonavir,
dasabuvir pack), the European Association for the Study of the
Liver, (EASL)37 and the American Association for the Study of
Liver Disease/Infectious Disease Society of America (AASLD/
IDSA).38
Key points:
▸ The DAA regimens have high cure rates across diverse popu-
lations in the real world
▸ Choice of optimal treatment regimen, duration and addition
of ribavirin are well expressed in recent treatment guidelines
▸ Adherence to treatment is likely to be crucial for success
Questions:
▸ How can we optimise adherence in newly diagnosed
patients?
Treatment of hard-to-treat groups
With the arrival of new therapies, the old rules about which
patients are difficult to treat for HCV and should be deferred
for future treatment have dramatically changed. Here we con-
sider four key ‘hard-to-treat’ groups: G3, co-infection with HIV,
renally impaired and those with drug and alcohol misuse.
Treatment of patients with decompensated cirrhosis or liver
transplantation who are in more urgent need for treatment is
addressed separately in the following chapter.
When PR was the mainstay of treatment, G1 was the geno-
type least responsive to drug therapy. Since the introduction of
DAAs, G3 has become the most difficult. Twenty-four weeks
of sofosbuvir and ribavirin is required to achieve SVR rates of
90%, with a sharp drop-off in SVR rates among
treatment-experienced patients with cirrhosis to only 60%,28 31
rising to 73% with the addition of ledipasvir for 12 weeks, also
in treatment-experienced patients.46 The combination of dacla-
tasvir/sofosbuvir shows rates of approximately 95% for patients
without cirrhosis, but SVR rates drop sharply when cirrhosis is
present.47 Other real-world experience in patients without cir-
rhosis with G3 infection showed SVR rates of approximately
90% with sofosbuvir/daclatasvir±ribavirin given for 24 weeks.48
Thus, the recent European Association for the Study of the
Liver (EASL) clinical practice guidelines and AASLD/IDSA HCV
Guidance recommend that G3 patients with cirrhosis should be
treated with sofosbuvir/daclatasvir and ribavirin for 24 weeks to
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maximise the chance of SVR.37 38 This is based on evidence
showing good efficacy of sofosbuvir/daclatasvir in compassion-
ate use programme.49 Currently, this is an argument to treat
G3-infected patients before the stage of cirrhosis to improve the
SVR rate based on sofosbuvir/daclatasvir for a shorter duration
(12 weeks) without ribavirin. One of the current questions in
the difficult-to-treat patients, especially those with G3 infection,
liver cirrhosis and previous treatment failure, is the use of riba-
virin in the DAA regimen.37 Indeed, besides the results of
cohort studies and trials,37 ribavirin was shown to reset
IFN-responsiveness in HCV-infected liver through epigenetic
changes in the liver, which may explain the clinical observations
in patients receiving IFN-free regimen via the action of
endogenous IFN in the liver microenvironment.50 51 It was also
interesting to see in a small study of ledipasvir/sofosbuvir given
for 12 weeks in G3-infected patients that the SVR rate increased
from 64% (16/25) to 100% (26/26) with the addition of
ribavirin.36
HIV co-infection is much less problematic than it was in the
PR days. SVR rates have improved dramatically with the new
therapies, to the extent that co-infected patients now achieve
SVR rates similar to mono-infected patients. Recent studies
showed high SVR rates of 96% in G1-infected or G4-infected
patients treated with sofosbuvir/ledipasvir for 12 weeks,52 and
97% across G1–G4 in patients receiving sofosbuvir/daclatasvir
for 12 weeks, but a decreased SVR rate to 76% when sofosbu-
vir/daclatasvir administration was shortened to 8 weeks.53 This
is reflected in the EASL37 and AASLD/IDSA38 recommendations
for HCV treatment, which give identical treatment recommen-
dations for co-infection and mono-infection. The main chal-
lenge with HCV treatment in co-infected patients is
management of DDIs, especially with HCV regimens containing
PIs. People who have been infected with HIV for decades are
often on second line or salvage therapy, which frequently
includes a boosted PI. HIV PIs and HCV PIs are metabolised by
the same pathway and have severe interactions. The EASL
guidelines recommend prioritisation of patients with HIV
co-infection for treatment, regardless of fibrosis level, because
of their higher risk of liver disease progression.37 Rates of
re-infection with HCV are considerably higher among the HIV
co-infected population than in other high-risk groups, with a
5 year post-SVR re-infection rate of 21.7%. By comparison,
5 year post-SVR re-infection rates among intravenous drug users
and prisoners are 13.2%, and among low-risk populations are
1.1%.54 Besides antiviral treatment in HCV-HIV co-infection to
reduce the pool of infected people, strategies for changing
sexual behaviour are urgently needed to avoid re-infection and
repeated treatments as traumatic sex practices with high risk for
blood-blood contacts remaining the main transmission risk
factor in HIV-seropositive men having sex with men (MSM).54
Patients with renal insufficiency and on dialysis are a challen-
ging population to treat, with high need but few treatment
options. The toxicity of ribavirin is significantly increased by
renal impairment. Sofosbuvir, now a mainstay of treatment, is
contraindicated in patients with a glomerular filtration rate
(GFR) below 30 mL/min. Recently, 28 patients without cirrhosis
with severe renal insufficiency (creatine clearance <30 mL/min/
1.73 m2, of whom 13 were on haemodialysis) were treated with
paritaprevir/ritonavir+ombitasvir+dasabuvir for 12 weeks with
(G1a) or without (G1b) ribavirin at 200 mg/day. Ten out of 10
patients achieved SVR4. Ribavirin was stopped in 8 out of 13
patients and 4 received erythropoietin (EPO).55 This small
study, while preliminary, suggests this combination may be a
treatment option for this patient population. The grazoprevir
+elbasvir combination was evaluated in 116 G1-infected
patients with end-stage renal insufficiency of whom 77% were
on haemodialysis. Nineteen per cent achieved SVR12. One
relapse was observed in a non-cirrhotic G1b patient. No dose
adaptation and no treatment cessation were necessary during
the study.56 This study provided promising treatment options
for this patient population.
There are very few data to assess how DAAs will affect clinical
outcome in patients with extrahepatic manifestations of chronic
hepatitis C.57 While it is clear that the presence of mixed cryo-
globulinaemia was a predictive factor of poor response to
IFN-based therapy,58 to what extent the use of DAAs may
change treatment outcomes in this group of patients deserves
further study.
There are little data to assess how DAAs will affect treatment
of patients who misuse drugs and alcohol. Studies carried out
in the PR era showed that patients on substitution therapies
such as methadone or buprenorphine achieved SVR rates close
to those seen in non-drug injecting populations,59 suggesting
that DAA therapy too will be feasible in this group. As
IFN-free therapies promise fewer contraindications, many
patients who would not have been considered for HCV
therapy in the past because of psychological comorbidities will
now become candidates for treatment. Adherence has always
been a problem in this group and it is known that adherence
declines after week 6 of treatment.60 Shorter treatment regi-
mens (<12 weeks) might be very helpful in this setting. As we
have already discussed for the HIV co-infected patients, there
is also a heightened risk of reinfection in this population.54
However, it is reasonable to assume that treatment of HCV
infection in this population should lead to a decreased burden
of the virus and in turn in a decreased transmission of the
infection. Antiviral treatment should be included in global pro-
grammes including lifestyle interventions and management of
addictions.
Key points
▸ Some G3-infected patients remain hard to treat, especially
those who are treatment-experienced with cirrhosis
▸ HIV co-infection is no longer a factor affecting SVR rates
although DDIs add complexity to management
▸ Patients with renal insufficiency have limited treatment
options, especially those on dialysis
Questions
▸ Does ribavirin add to efficacy of DAA treatment in G3?
▸ What is the effect of DAA on extrahepatic manifestations of
HCV infection ?
▸ How do we minimise the rates of re-infection in high-risk
groups?
▸ Which interventions aid adherence to treatment for drug and
alcohol users?
Treatment in patients with decompensated cirrhosis and LT
In the past, patients with decompensated cirrhosis were rarely
offered treatment, as IFN based regimens were poorly tolerated
and associated with significant risk of complications. All-oral
DAA combinations offer the opportunity to treat these patients,
although the only combinations licensed for patients with severe
liver disease (Child-Pugh B or C) are sofosbuvir/ledipasvir or
sofosbuvir/daclatasvir, with or without ribavirin.37 38 This
should take into account that renal dysfunction typically accom-
panies advanced liver disease and the options are further
limited, as sofosbuvir is not approved for use in patients
with creatinine clearance <30 mL/min. However, patients with
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decompensated cirrhosis have much to gain with successful
therapy, including improvement in liver function and reversal of
symptoms of decompensation. Since survival in persons with
decompensated cirrhosis in the absence of treatment is on
average only 2 years,61 there is a limited time period to inter-
vene with treatment.
Results from treatment-experienced patients with compen-
sated cirrhosis given sofosbuvir+ledipasvir, show that similar
SVR results were achieved with the addition of ribavirin as a
12-week regimen or the extension of treatment to 24 weeks.19
In studies in decompensated cirrhosis treated with sofosbuvir
+ledipasvir and ribavirin, ∼85% of G1 patients with
Child-Pugh B or C cirrhosis achieved SVR with 12 weeks of
treatment.20 Results of compassionate access studies report 80%
SVR rates with sofosbuvir and daclatasvir with and without riba-
virin for 12 weeks.62 Collectively, results show lower SVR rates
in patients with decompensated cirrhosis than other treatment
groups, and severity of liver dysfunction (Child-Pugh class) and
portal hypertension (as indicated by platelet count) may identify
patients with lower likelihood of achieving SVR.
While SVR is important, the additional goals of therapy in
patients with decompensated cirrhosis are clinical stabilisation,
reversal of decompensation, improved survival and reduced
need for LT. Studies in patients with Child-Pugh B/C cirrhosis
treated with ledipasvir+sofosbuvir for 12 weeks showed Model
for End-Stage Liver Disease (MELD) scores improved in the
majority of patients (17 of 30 with Child-Pugh class B; 13 of 23
with Child-Pugh class C).20 However, some patients improved
by only one or two points, some had no improvement and some
deteriorated. Greater improvements may be evident with longer
follow-up after SVR but whether the improvements obtained
will be sufficient to reverse or prevent all complications of cir-
rhosis and avoid LT is unknown. Since access to LT is deter-
mined by MELD score and SVR may diminish MELD score,
successful treatment may reduce the likelihood of getting a LT
and this makes the timing of treatment a challenge. For some
patients, having a LT is most important, and deferral of HCV
treatment until after LT may be a better option.
The situation is different for people with cirrhosis listed for
LT for HCC or other exceptions for whom access to LT is not
dependent on severity of liver disease. In a study of treatment
with sofosbuvir plus ribavirin up to the time of LT in
Child-Pugh A patients with HCC, all patients achieved
undetectable viral load on treatment, and among those who
had a transplant, 70% were HCV-free post LT. The success of
this approach increased to 96% if patients had HCV RNA
levels below the lower limit of quantification for ≥4 weeks pre-
transplant.63 The treatment strategy works best in living donor
transplants and for patients with exception status as treatment
can be timed to LT. Even in those select patients, this strategy
can be challenging since time to HCV RNA negativity varies
and LT time is not always precisely predictable. To our knowl-
edge, there are no data available regarding the impact of DAA
therapy in patients with HCC outside the LT context, in terms
of HCC recurrence or mortality. Currently, one might recom-
mend DAA therapy in all patients undergoing a curative treat-
ment for HCC.
Historically, transplant recipients were considered a
difficult-to-treat group with low SVR rates and poor tolerability
of therapy. This has changed completely with IFN-free DAA
combinations. With current all oral HCV therapies, SVR rates in
LT recipients appear comparable to non-transplant
patients.23 63 64 Regimens that include a PI have added com-
plexity due to DDIs with immunosuppressant therapy. Since
renal dysfunction is a frequent post-LT complication, recipients
with concurrent disease and estimated glomerular filtration rate
(eGFR) less than 30 mL/min have more limited treatment
options.
Key points:
▸ Treatment options are more limited in decompensated
cirrhosis
▸ Achievement of SVR can result in clinical improvement for
patients with advanced disease, but this is not universal
▸ HCV therapies used post transplant appear to achieve rates
of viral eradication similar to non-transplant patients but
DDIs need to be considered.
Questions:
▸ Is it better to treat patients with advanced disease before or
after liver transplantation?
▸ How does pre-transplant treatment failure affect post-trans-
plant treatment success?
▸ What are the consequences of treatment failure (ie, drug
resistance) post-transplant?
Management of DAA failure
One of the emerging questions is the management of patients
who have failed a DAA-based treatment. Currently, most of
these patients have been treated because of severe underlying
liver disease. Therefore, rescue antiviral therapy seems manda-
tory in these patients, although the optimal antiviral regimen is
not known. Should we re-treat with the same DAA class, or a
different class? If we use the same DAA class, we might consider
delaying treatment in the hope that acquired resistant mutations
to treatment disappear. This is based on experience with the
first generation of PIs, where the virus of G1 patients who failed
treatment reverted to non-resistant wild type virus at a median
of 1 year.65 This may not be realistic for patients with advanced
disease, and it may not be relevant to patients treated with
IFN-free therapy and other DAA classes. Data about patients
who failed on the NS5B inhibitor sofosbuvir show that resistant
variants are uncommon and revert to wild type quickly, leaving
the opportunity to re-treat early.66 PI resistant variants selected
after treatment failure tend to return to baseline levels rapidly
and are detectable only in a minority of patients 48 weeks after
treatment cessation. Conversely, NS5A inhibitor resistance tends
to persist. Resistance-associated variants (RAVs) to ombitasvir
were detected in 98% of patients who failed 3D therapy at
24 weeks, and in 96% at 48 weeks post treatment,67 suggesting
that patients who failed NS5A inhibitor containing regimens
represent a challenging population.
Some data exists to assess the efficacy of re-treating with the
same class of DAA. Patients who failed on a PI regime and were
treated again with simeprevir+sofosbuvir with or without riba-
virin showed a 4-week SVR of 81%, compared with 89% for
patients who had not previously failed with a PI. This suggests
SVR is likely to be slightly lower in these patients,39 but is con-
sistent with the kinetics of disappearance of PI-resistant variants
described above. Further data on patients who had failed sofos-
buvir and ribavirin and were then treated again with a combin-
ation of sofosbuvir+ledipasvir plus ribavirin show that 44 of 45
achieved an SVR on re-treatment, suggesting that re-treatment
may be effective when associated with an NS5A inhibitor.68
Few data are available for assessing retreatment of patients
who have failed NS5A inhibitors, although a study showed that
patients who have baseline RAVs associated with limited efficacy
had a higher relapse rate (31%). This could be used as proxy
data, although treatment duration was short (12 weeks) and
ribavirin was not used (sofosbuvir/ledipasvir Summary of
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Product Characteristics (SmPC)). The same finding was reported
in a recent study investigating re-treatment with 24 weeks of
sofosbuvir/ledipasvir in G1 patients who had failed the same
combination for 8–12 weeks. Overall SVR rates were 71% but
by stratifying patients on the presence of baseline RAVs in the
NS5A region, the authors found that those with RAVs achieved
an SVR in 60% of the cases compared with 100% in those
without RAVs.69 The question whether ribavirin could have
increased SVR rates remains unanswered as it was not part of
the studied regimen.
From a virological standpoint, the recommendation is to treat
patients with another DAA class, to avoid cross-resistance issues.
Data on re-treatment of people who had failed PI treatment,
using a sofosbuvir/ledipasvir combination with or without riba-
virin, showed the same SVRs as non-treatment-experienced
patients.18 Another study of this combination, in people with
compensated cirrhosis who had previously failed on PI, showed
SVR of 96–97%.19 Changing the regimen looks to be a highly
effective strategy. These data are reflected in the 2015 EASL
guidelines, which suggest re-treatment of patients who have
failed on a DAA-containing regimen with an IFN-free combin-
ation that includes a drug with a high barrier to resistance (cur-
rently sofosbuvir) and one or two other drugs without
cross-resistance to the drugs already tried. The EASL committee
suggests using a regimen suitable for ‘hard-to-treat’ patients, by
extending the duration of treatment to 24 weeks and adding
ribavirin.37
The outstanding question is how to address the patient who
fails on the 3D regimen of paritaprevir(r), ombitasvir and dasa-
buvir, which combines all available DAA classes. The option of
returning to a combination with pegylated IFN is not attractive;
sofosbuvir as a nucleotide NS5B inhibitor (different from the
non-nucleoside inhibitor dasabuvir) might serve as a backbone
to the rescue therapy with pegylated IFN.70 However, unless
new classes become available, it may be a last-resort therapeutic
option. Another question to be addressed is the clinical rele-
vance of testing for RAVs before starting re-treatment in patients
who failed a previous DAA-containing regimen. Indeed, the dif-
ferent levels of drug resistance, viral fitness, and cross-resistance
of the selected RAVs may affect treatment decisions, but this
needs to be evaluated prospectively in the context of a rapidly
evolving therapeutic field. By contrast, in treatment-naïve
patients, detection of RAVs prior to therapy is not clinically
useful because of the very high SVR rate in this situation.17
Key points:
▸ Limited data are available to guide ‘next’ treatment choices
in patients who fail to achieve SVR with DAA combination
therapy
▸ Deferral of treatment pending more data may be appropriate
for patients who are not in need of immediate retreatment
▸ Currently, people who have failed DAA treatment are likely
to have advanced disease and be in need of more immediate
re-treatment
▸ Re-treatment including a different class of DAA without
cross-resistance gives good results
▸ Patients who relapse after treatment with an all-oral combin-
ation have RAVs that will persist for a variable duration of
time post treatment
Key questions:
▸ Should patients with milder disease wait before retreatment?
▸ How can we treat people who fail the 3D regimen and those
who failed several lines of DAA-based therapy?
▸ Should ribavirin be considered in re-treatment of a DAA
failure?
Future drug development
As noted above, while huge progress has been made over the
past 5 years, HCV still presents challenges. Drug development
continues for new therapies and combinations which may
address some of these challenges. Priorities for next generation
DAA combinations include regimens which:
▸ Are truly pan-genotypical, with high efficacy against all geno-
types and subtypes
▸ Allow for shorter duration of treatment
▸ Include coformulated drugs and dispense with the need for
ribavirin
▸ Have limited DDIs
▸ Result in an SVR for more than 95% of patients at all levels
of fibrosis
▸ Treat prior DAA failures and have low resistance rates
▸ Treat special groups including people with HIV, post-
transplant patients, people with end-stage renal disease and
possibly children
Two new combinations expected in 2016 include sofosbuvir
with the new NS5A inhibitor GS5816 (velpatasvir), and a
double or triple regimen including the new PI grazoprevir and
the new NS5A inhibitor elbasvir, possibly with the addition of
an NS5B inhibitor.
Data for the sofosbuvir/GS5816 combination in treatment-
naive patients demonstrate good results across genotypes for
12 weeks of treatment at 100 mg dose of GS5816. Results from
8 weeks of treatment and lower doses were suboptimal.71 The
study found ribavirin had no effect on SVR in this group of
patients and there were no significant safety signals. In
treatment-experienced patients, the combination also appeared
safe and effective for 12 weeks without ribavirin. SVR rates
were significantly lower in GT3 patients, especially those with
cirrhosis, where higher dose (100 mg vs 25 mg) was clearly
required.72 Overall, this combination seems to provide better
results in the difficult-to-treat populations compared with sofos-
buvir/ledipasvir.
Early proof-of-concept studies of triple therapy (sofosbuvir,
ledipasvir and the non-nucleotide NS5B polymerase inhibitor
GS9669 or the NS3 PI GS9451) showed high cure rates after
6 weeks of therapy. Particularly interesting was that some
patients who finished the 6 week study with detectable HCV
RNA levels went on to have an SVR within 14–21 days.73 If this
finding can be replicated, it could change the treatment para-
digm with shorter duration treatments. How short can treat-
ment regimes get? Interim data from a study of a
nucleotide-based triple regimen (PI grazoprevir plus NS5A
inhibitor elbasvir plus sofosbuvir) showed that some patients do
respond within 4 weeks of treatment, but most need 8-week or
6 week regimens.74 Identifying patients who will respond to
shorter durations of treatment with some degree of certainty
will be a challenge. An analysis of treatment outcomes by base-
line resistance-associated variants demonstrated that patients
with specific RAVs treated with this regimen had a lower SVR
(38% vs 75%).74
Results from another study of new generation NS5A inhibitor
ACH-3102 combined with sofosbuvir (as a proxy for an NS5B
inhibitor in development) in a phase 2 study showed 12 of 12
treatment-naive G1 patients achieved SVR12, and that all of
them had shown a viral load below the lower limit of quantifica-
tion after 4 weeks of treatment.75
One promising avenue for the new NS5A inhibitors is their
use against different genotypes and subgenotypes. The NS5A
inhibitor MK-8408 is pan-genotypical and demonstrates in vitro
activity against known clinically relevant RAVs. The new
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nucleoside MK-3682 demonstrates potency against G2 and G3,
with significant reductions in viral load after only 7 days’
dosing.76
Finally, future treatment could use small-molecule entry inhi-
bitors or monoclonal antibodies to prevent HCV from entering
liver cells. Animal experiments demonstrate how this approach
could prevent infection and reduce persistent infection.77–79
This route may be worth exploring for patients preparing for
transplant, in order to prevent infection of the graft as well as in
patients with RAVs to prevent their spread in association with
other DAAs.
Key points:
▸ The DAA pipeline continues to deliver IFN-free treatments
and most patients in future will not need ribavirin
▸ Treatment resistance may be a growing problem
▸ Drugs with pan-genotypical activity are in the pipeline
Questions:
▸ Can we identify patients who could benefit from short treat-
ment regimens of 6 weeks or less with newer DAA combin-
ation therapies?
Access to treatment: high-income countries
DAAs are expensive and available resources are limited, even in
high-income countries. We have to evaluate new treatment strat-
egies to optimise the medical intervention and make the most of
the resources available. While costs of treatment are ‘upfront’,
the benefit expected from lower healthcare costs will be accrued
over decades. One challenge is to find novel financing mechan-
isms to defray those upfront costs.
Cost-effectiveness analyses consider how effective a new tech-
nology is compared with existing technologies, and whether this
additional benefit is worth the additional costs. This is often
considered in terms of cost per quality-adjusted life year
(QALY). Acceptable costs per QALY vary by country, although a
benchmark of around US$50 000 is often discussed.80 Two
recent publications compared sofosbuvir-based treatment regi-
mens for HCV to the standard of care in the USA. The first
showed an overall cost of US$55 400 per QALY gained.
However, the cost per QALY varies considerably in different
populations: as low as US$9700/QALY gained for G1 treatment-
naive patients with cirrhosis, rising to US$410 500/QALY gained
for G3 treatment-experienced patients without cirrhosis.81
A comparison of IFN-free regimens versus standard of care
found that the costs per QALY varied by genotype and regimen:
from US$12 825/QALY gained for sofosbuvir/ledipasvir for G1
to US$691 574/QALY gained for sofosbuvir/daclatasvir for G2.
Overall the figures suggest that DAAs offer substantial public
health benefits at a reasonable cost per treated patient, in
selected groups.
Costs per QALYs are sensitive to the stage of fibrosis when
treatment is initiated. The more advanced the fibrosis, the lower
the cost per QALY. This can be seen across genotypes, and over
several different treatment regimens. It may not be cost-effective
to treat patients with G1 before they are at fibrosis stage 2.82
Age is also a factor; treating younger patients clearly saves more
QALYs than older patients. By this analysis, treating patients
over the age of 70 years does not result in a cost/QALY gained
under $50 000, for any genotype or treatment regimen.
Treating patients over the age of 50 years may not be cost-
effective in G2 or G3. This raises a fundamental question about
how to treat older patients, who could benefit from improve-
ments to quality of life. A threshold analysis evaluated treatment
costs to cost-effectively treat patients at fibrosis stage F0, com-
pared with treatment at stage F2, given a range of assumptions
and a cost-effectiveness threshold of $100 000 per QALY.83 It
showed treatment costs could range from around $20 000
for less effective drugs to around $45 000 for highly effective
drugs. Patients aged 40 years can be cost-effectively treated by a
course costing around $55 000, which drops to below $20 000
for patients aged 70 years.
Even if the new DAA therapies are cost-effective in selected
groups, they are not cost-saving and affordable at their current
prices. Treating all eligible patients with HCV would have an
immense impact on health service budgets, unless it is planned
over a 10 year period, allowing progressive treatment for
patients with lower fibrosis scores. Another issue will be how to
identify the undiagnosed HCV carriers who are not seeking
medical care. Therefore the current challenge in the HCV field
is now treatment access. If these regimen prices remain at the
current levels, the treatment of patients with HCV will require
additional resources and value-based patient prioritisation.
Limiting access to therapy, usually based on the severity of the
disease, is one strategy to address the question of cost. However
this generates some difficulties: it is difficult to accept for
patients with less severe disease and will delay progress towards
HCV elimination. It may also decrease the success rate as it was
discussed for G3-infected patients. Attempting to convince
patients with HCV and their advocates that cost-spreading via
patient prioritisation is not discrimination but a way to make
treatment for everyone more manageable in the long term, may
be the most rational approach. However the simplest approach
is probably to lower the costs of the drugs.84
Key points
▸ DAAs are cost-effective in certain patient groups, but this
varies by genotype, stage of fibrosis and age
Questions
▸ How do we prioritise treatment in cost-effective areas?
▸ How can clinicians explain the need to treat priority patients
first, without failing lower-priority patients?
▸ How to lower drug costs to increase access to treatment?
Access to treatment: low-income and middle-income
countries
Improving access to treatment for HCV-infected people in low-
income and middle-income countries requires consideration of
the burden of hepatitis C infection, knowledge of how many
people require treatment, strategies to reduce the price of drugs
and improved logistics to allow use of therapies.3 The task is
hampered by missing data. There is no consensus on how many
people are infected with HCV worldwide. WHO estimates
between 130 million and 150 million people have chronic
HCV infection. Prevalence is highest in Africa and Asia.85
Most people with chronic HCV live in middle-income countries
with the greatest numbers living in China, Pakistan, and
Nigeria.86 These are not countries that attract the interest of
traditional aid donors. There are even less data to assess how
many people need treatment. There are no population-based
studies that assess the distribution of fibrosis stages. The
numbers actually diagnosed and treated are low, but most of the
results come from European countries.87 Less than 5% of
infected people in low-income countries know they are infected,
and few of these have access to treatment.
Before considering the price of drug treatment, we should
consider the obstacles for introducing wide-scale HCV treat-
ment in low-income and middle-income countries. First, people
need to be aware that they are at risk of infection, in order to
come forward for testing. Confirming chronic HCV infection
requires a nucleic acid test, which is not available everywhere.
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Assessment for treatment eligibility then requires testing for
degree of fibrosis, genotype and viral load. The health system
requirements for this to happen are high including trained
healthcare workers and well-equipped laboratories. At present,
HCV treatment is the domain of hepatologists. To reach all
those who need treatment, treatments have to be devolved to
primary care doctors, which means that treatment needs to be
standardised and simplified. One of the benefits of the newly
emerging treatments is the hope for a dramatic simplification
of the treatment cascade. Pan-genotypical drugs that are safe
and effective regardless of fibrosis could remove the need for
HCV genotyping and fibrosis assessment. We could foresee a
treatment pathway that requires a rapid diagnostic test of
HCV antigen to diagnose the disease, with a repeat antigen
test after treatment to confirm success using point-of-care
tests.
Price of drug treatment remains key. Prices have dropped
quickly. Sofosbuvir has a list price of US$84 000 for 12 weeks
of treatment per patient in the USA, but this has dropped to
US$900 in Egypt. However, the manufacturing cost is esti-
mated at US$68 to US$136 for sofosbuvir so lower costs
should be possible and should become a reality with the
introduction of generic formulations of DAAs.88 Within the
next 15 years, large-scale manufacture of two or three drug
combinations of HCV DAAs is theoretically feasible, with
minimum target prices of US$100–250 per 12-week treat-
ment course. These low prices could make widespread access
to HCV treatment in low-income and middle-income coun-
tries a realistic goal.88 The implementation of response
guided therapy with IFN does not seem the best approach, as
patients with the highest chance of achieving SVR usually can
wait to have more affordable and even more effective treat-
ments. Furthermore, the main issue as mentioned earlier will
be to identify the undiagnosed patients; by that time, we can
expect that DAA-based regimens will be more accessible.
Antiretroviral treatment for HIV began with very high costs,
which plummeted after the introduction of generic drugs.
But the HIV story demonstrates what is lacking in HCV.
Pressure on HIV drug pricing came from strong advocacy,
initially driven by the MSM community in the USA and
Europe. Large donors were active in low-income countries,
and large-scale bulk purchases by donors such as the
Global Fund created a large market for generics manufac-
turers, and through competition, significant price reductions.
As HCV lacks a strong advocacy group, middle-income coun-
tries tend to be left to fend for themselves without these
drivers.
There are several options to increase affordability of HCV
drugs:
▸ Voluntary licensing agreements, whereby patent holders
license their drugs to generic companies and provide technol-
ogy transfer. However, medicines can only be marketed in
specific, generally low-income, countries. An example of this
is the voluntary licensing agreement announced by Gilead,
which has issued voluntary licenses to 11 Indian generics
manufacturers, which will be able to make their generic
drugs available to 103 low-income and middle-income coun-
tries, excluding China.
▸ Differential pricing, where the patent holders negotiate a
price reduction country by country. Prices tend to remain
higher than those of generics and agreements are usually
confidential.
▸ Patent oppositions, where countries take legal action to argue
that a new drug does not demonstrate sufficient innovation
to qualify for a patent. This is usually a lengthy process.
Patents for sofosbuvir have been declined in China, Egypt
and India.
▸ Compulsory licensing, where a country decides based on its
public health needs that drugs can be manufactured locally,
or cheaper generic drugs can be imported. This approach is
rarely used, as there is usually significant political opposition
to compulsory licensing and local production of generics can
be technically challenging. Bangladesh and Egypt are starting
local manufacture of DAAs outside of the licensing
agreements.
To speed access to treatment for low-income and
middle-income countries, WHO is developing a global hepatitis
strategy with a goal of eliminating HCV as a public health threat
by 2030. It has included key HCV drugs on the Essential
Medicines List and is producing updated treatment guidelines
that will include preferred treatment regimens by the end of the
year.
Key points
▸ The complexity of HCV diagnosis and treatment hamper
access to therapy, even without high drug costs
▸ Simplified regimens may overcome this obstacle
▸ HCV lacks the strong advocacy and bulk purchasing through
global-donor mechanisms that drove price decreases in HIV/
AIDS
Questions
▸ Which of the current strategies for increasing access to HCV
therapies in low-income or middle-income countries will
work best?
CONCLUSION
Without doubt, the introduction of DAA therapies in HCV have
transformed the treatment landscape and offer a brighter vista,
which could even include eradication of this burdensome
disease. With notable exceptions, most patient populations
would now benefit from IFN-free therapy.
The expense of treatment, coupled with medical capacity,
means that priority patients must be treated first. But once that
job is underway, interesting questions arise about how and
when to treat the remaining patients. More patients under
treatment will mean more treatment failures, with the chal-
lenges that that brings. Resistance to therapy is likely to
become a more significant problem, thus arguing for an opti-
misation of the current treatment management on an individ-
ual basis. Antiviral drugs currently under development may
also address that question.
HCV therapy is undergoing a true medical revolution that
still faces many challenges. The ongoing clinical research and
the mobilisation of health stakeholders should hasten the path
towards an eradication of the disease within the next decade.
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